Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Application of Desferal to Treat COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04333550
Recruitment Status : Recruiting
First Posted : April 3, 2020
Last Update Posted : May 4, 2020
Sponsor:
Information provided by (Responsible Party):
Dr. Yadollah Shakiba, Kermanshah University of Medical Sciences

Brief Summary:
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Deferoxamine Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations
Estimated Study Start Date : April 2020
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental: Desferal addition to standard treatment Drug: Deferoxamine
Intravenous infusion of Deferoxamine

Experimental: Experimental: standard treatment Drug: Deferoxamine
Intravenous infusion of Deferoxamine




Primary Outcome Measures :
  1. Mortality rate [ Time Frame: up to 20 days ]
    All cause of death


Secondary Outcome Measures :
  1. change in patients clinical manifestation [ Time Frame: up to 20 days ]
    Mild, Moderate or Severe

  2. change in patients PaO2 [ Time Frame: up to 20 days ]
  3. Length of hospitalization [ Time Frame: up to 20 days ]
    days

  4. C-reactive protein [ Time Frame: up to 20 days ]
  5. lymphocyte count [ Time Frame: up to 20 days ]
  6. length of intensive care unit stay [ Time Frame: 1 to 20 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Clinical diagnosis of COVID-19 Disease,

Exclusion Criteria:

Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04333550


Contacts
Layout table for location contacts
Contact: Alireza Ghaffarieh, MD +1-608-698-7334 alirezaghaffariyeh@hotmail.com
Contact: Yadollah Shakiba, MD, PhD yshakiba@gmail.com

Locations
Layout table for location information
Iran, Islamic Republic of
Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Recruiting
Kermanshah, Iran, Islamic Republic of, 083
Contact: Yadollah Shakiba, MD, PhD         
Sponsors and Collaborators
Kermanshah University of Medical Sciences
Investigators
Layout table for investigator information
Study Director: Yadollah Shakiba, MD, PhD Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Principal Investigator: Amir Kiani, PhD Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Publications of Results:

Layout table for additonal information
Responsible Party: Dr. Yadollah Shakiba, Dr. Yadollah Shakiba, MD, PhD, Kermanshah University of Medical Sciences
ClinicalTrials.gov Identifier: NCT04333550    
Other Study ID Numbers: 1398.1224
First Posted: April 3, 2020    Key Record Dates
Last Update Posted: May 4, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Yadollah Shakiba, Kermanshah University of Medical Sciences:
COVID-19, Deferoxamine
Additional relevant MeSH terms:
Layout table for MeSH terms
Deferoxamine
Siderophores
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action